Trial to Evaluate Safety and Tolerability of GP-2250 in Combination With Gemcitabine

NCT03854110 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

64

Enrollment

INDUSTRY

Sponsor class

Conditions

Pancreatic Cancer, Adult

Interventions

DRUG: GP-2250

Sponsor

Geistlich Pharma AG

Collaborators

[object Object]